Analytical Data
-
Gene name
TRAF4
- Application
-
Alternative Names
CART1; MLN62; RNF83; Cysteine-rich domain associated with RING and Traf domains protein 1; Metastatic lymph node gene 62 protein; RING finger protein 83
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BUZ4
-
Expression Region
Gln193~Asp444
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TRAF4 (TNF Receptor-Associated Factor 4) is a member of the TRAF family of adaptor proteins that play crucial roles in various cellular processes, including immune response, inflammation, and cell signaling. Research indicates that TRAF4 is involved in modulating signaling pathways associated with several cytokine receptors, including tumor necrosis factor (TNF) receptors and interleukin receptors. Abnormal expression or function of TRAF4 has been linked to various diseases, including cancer, autoimmune disorders, and inflammatory conditions, highlighting its significance in pathophysiology. The recombinant TRAF4 protein has garnered attention for its potential as a therapeutic target and as a tool for studying the mechanisms of TRAF4-mediated signaling pathways. The generation and characterization of recombinant TRAF4 allow researchers to dissect its functional roles, understand its interactions with other proteins, and explore its contribution to disease mechanisms. Additionally, investigating TRAF4's structural properties can provide insights into its functional domains and binding affinities, paving the way for the development of novel therapeutic interventions aimed at modulating TRAF4 activity in disease contexts. As such, the study of TRAF4 recombinant protein is essential for uncovering the intricacies of immune signaling and developing targeted therapies that could improve patient outcomes in TRAF4-related diseases.
